The Hospitalist Online Background: Current guidelines recommend bridging with heparin or LMWH for patients at high risk for thromboembolic events around the time of pacemaker or ICD placement, but it is associated with significant risk of device-pocket hematoma. Some centers ...
News-Medical.net In the treatment of venous thromboembolism (VTE), the oral anticoagulant edoxaban resulted in equal efficacy and better safety compared to standard warfarin when either drug was used with initial low molecular weight heparin (LMWH), according to the ...
Wall Street Journal 05803391.1, "Antimicrobial Locking Solutions Comprising Taurinamide Derivatives and Biologically Acceptable Salts and Acids, with the addition of Small Concentrations of Heparin " which CorMedix refers to as the "Prosl" patent application. The Prosl ... and more »
Healio AMSTERDAM — Once-daily edoxaban administered after initial treatment with low–molecular-weight heparin was noninferior to standard therapy and associated with less bleeding in patients with venous thromboembolism, including those with severe ...
Science Daily (press release) 1, 2013 — Use of the novel anticoagulant otamixaban did not reduce ischemic events compared with unfractionated heparin plus eptifibatide but increased bleeding among patients with non-ST-segment elevation acute coronary syndromes undergoing a ...
Daily Press In addition to the shareholders vote, the acquisition is also being vetted by federal agencies to make sure it doesn't threaten national security. A House co...
Monthly Prescribing Reference The researchers found that the rates of a composite of all-cause death or new myocardial infarction through day seven were 5.5% in otamixab...
